Report from the XVI International HIV Drug Resistance Workshop.
Kuritzkes
Daniel R
DR
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003510:Cyclohexanes / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000627:therapeutic use; D006801:Humans; D061466:Lopinavir; D000077592:Maraviroc; D009570:Nitriles; D010879:Piperazines / Q000627:therapeutic use; D011724:Pyridazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use
D019380:Anti-HIV Agents; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D019428:HIV Integrase Inhibitors; D009570:Nitriles; D010879:Piperazines; D011724:Pyridazines; D011743:Pyrimidines; D011744:Pyrimidinones; D014230:Triazoles; C451734:etravirine; D061466:Lopinavir; D000077592:Maraviroc; C486781:vicriviroc